FDA Accepts Supplemental Application for ZITHROMAX by Pfizer
The FDA has accepted a supplemental application for ZITHROMAX (azithromycin) from Pfizer.
Asset / Drug
Drug and asset intelligence for ZITHROMAX with 10 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The FDA has approved a supplemental application for Zithromax (Azithromycin) submitted by Pfizer.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.